In order to induce specific antitumor immunity in mice, we attempted to immunize C57BL / 6 mice with DNA vaccine encoding MUC1 polypeptide. When the mice immunized with MUC1 DNA were challenged with EL4 -muc, MUC1 -transfected syngeneic lymphoma cells, they completely rejected tumors. When DNA vaccine was given to the EL4 -muc tumor -bearing mice, this vaccination was insufficient to suppress tumor growth in the mice. However, activated, but nonprimed dendritic cells ( DCs ) obtained from syngeneic mice and MUC1 DNA vaccine were given simultaneously to the same site of EL4 -muc tumor -bearing mice, tumor growth was markedly suppressed accompanying prolongation of survival time. MUC1 antigen was detected on the DCs at the vaccination site and in regional nodes in the mice which received MUC1 DNA vaccine and DCs. These mice showed markedly enhanced cellular immune responses specific for MUC1 compared to those in mice vaccinated with MUC1 DNA alone. No significant difference in titers of antibodies to MUC1 between the two groups was observed. These results suggest that nonprimed DCs inoculated at the DNA vaccine site are essential for eliciting strong antitumor cellular immunity to suppress tumor growth efficiently in DNA -vaccinated mice. This animal model is useful for developing DNA vaccine for anti-cancer immunotherapy.
V arious immunotherapies for cancer, including vaccines, adoptive transfer of killer cells, and cytokine and antibody administration, have been developed. 1 -4 Immunotherapy with the agents, such as biological modifiers, lymphokine -activated killer (LAK ) cells, and various cytokines, which enhance general host defense mechanisms nonspecifically, has been reported to be much less effective clinically than expected results, with an exception of Bacillus Calmette -Guerin ( BCG ) vaccine against bladder cancer. 5, 6 This is mainly because the immunity enhanced by these treatments was not specific for tumor cells. Recently, vaccinations with autologous tumor cells or synthetic peptides derived from tumor-associated antigens ( TAAs ) have been applied for cancer immunotherapy. 7 -10 Immunotherapies with such vaccines sometimes induced tumor regression or prolonged survival, many such clinical trials being ongoing. Vaccination with DNA -encoding tumor antigens has been reported to be suitable for maintaining high levels of tumor antigen expression at the vaccination site, eliciting both humoral and cellular immunity specific for DNA -encoding antigens. 11, 12 For the induction of strong antitumor immunity by DNA vaccination, dendritic cells ( DCs ) located at the vaccination site are greatly responsible as antigen -presenting cells ( APCs ). 13 In experimental mouse models, tumor growth was suppressed successfully by vaccination with DNA -encoding tumor antigens. 14 -17 Among the specific cancer immunotherapies, DNA vaccines are thought to be more applicable for clinical use than other methods, such as vaccines with peptides or autologous cancer cells, or adoptive transfer of cytotoxic T lymphocytes ( CTLs ), because of the following reasons: (a ) DNA vaccines are inexpensive and simple to use once the DNA vector is prepared; (b ) adjuvants are usually unnecessary for DNA vaccination; ( c) high levels of antigen expression can be maintained; ( d) autologous immune cells or cancer cells are not needed; and ( e) facilities and techniques for cell culture are not necessary. Therefore, DNA vaccines targeting tumor antigens have great potential for anti-cancer immunotherapy.
MUC1 antigen is abundantly expressed in breast, pancreas, lung, and colon cancers, eliciting strong antitumor immunity in hosts. 18 -21 The tandem repeat domain on its core protein contains antigenic epitopes that are recognized by CTLs in both mice and humans. 22 -24 Therefore, MUC1 would be a suitable target for developing cancer immunotherapy.
In this study, we wanted to examine whether MUC1 DNA vaccination combined with simultaneous injection of activated, nonprimed DCs obtained from syngeneic mice could suppress tumor growth. Thereby, we report here a new DNA vaccine protocol that induces much enhanced anticancer immunity in murine model.
Materials and methods

Cells and mice
A murine lymphoma cell line, EL4, was purchased from American Type Culture Collection ( Rockville, MD ). The cells were maintained in DMEM medium supplemented with 10% heat -inactivated FCS, 2 mM L -glutamine, 100 U / mL penicillin G, and 0.1 mg /mL streptomycin (all from Gibco BRL, Tokyo, Japan ). Six -to eight -week -old female C57BL /6 mice were purchased from Charles River ( Hino, Japan ) and maintained under specific pathogen -free conditions.
Antibodies
Anti -MUC1 core monoclonal antibodies, DF3 and SM3, were provided by Toray -Fuji Bionics ( Tokyo, Japan ) and Cymbus Bioscience (Southampton, UK ), respectively. Horseradish peroxidase (HRP )-or fluorescence -conjugated anti -mouse and anti -rat IgG antibodies were purchased from ICN Pharmaceutical ( Aurora, OH ). Antimouse CD86 ( RMMP1 ) and MHC class II ( I1) monoclonal antibodies were from Immunotech ( Marseilles, France ) and Serotec ( Cambridge, MA ), respectively. Anti -mouse CD4 and CD8 monoclonal antibodies were purified from ascites of female severe combined immunodeficient mice ( Charles River ) that received peritoneal inoculation of hybridoma cell lines, GK1.5 and 2.43 ( American Type Culture Collection ), respectively, using Protein A -Sepharose column chromatography (Zymed Laboratories, San Francisco, CA ). Fluorescence isothiocyanate citrate ( FITC )-conjugated anti -mouse CD11c monoclonal antibody was purchased from PharMingen ( Tokyo, Japan ).
Synthetic peptides
Oligopeptides containing 30 amino acids, whose sequences corresponded to MUC1 tandem repeats ( TRPAPGSTAP-PAHGVTSAPDTRPAPGSTAP ) and Pan -IA peptides ( AEGFSYTVANKAKGIT ) that bind various haplotypes of I -A molecules and activate helper T cells, 25 were synthesized commercially by Kurabo (Osaka, Japan ).
Immunohistochemical and immunofluorescent staining
Muscle tissues resected from the vaccination site or paraaortic lymph nodes were frozen, sliced, and fixed with acetone. For immunohistochemical staining, the sections were incubated with anti -MUC1 core monoclonal antibody, DF3. After washes with phosphate -buffered saline ( PBS ), the sections were incubated in HRP -conjugated anti -mouse IgG, followed by incubation with substrate solution made of diaminobentizine and H 2 O 2 . For immunofluorescent staining, the sections were incubated with anti -CD86 or MHC class II monoclonal antibodies, then with FITC -conjugated anti-mouse or anti -rat IgG. After washes, the sections were studied on a fluorescence microscope.
Preparation of DCs
Bone marrow cells were obtained from the femurs of female C57BL / 6 mice and suspended in RPMI 1640 containing 2% FCS. Single cells were separated by filtration with a nylon filter, and washed with RPMI 1640 containing 2% FCS. The cells were resuspended in RPMI 1640 supplemented with 10% FCS, 50 ng /mL GM -CSF ( Genzyme, Cambridge, MA ), and 50 ng/mL IL-4 (Genzyme ), transferred to a 24 -well culture plate at a concentration of 1Â10 6 / mL, and cultured for 7 days. Then, nonadherent cells were harvested and used as DC source. The prepared cell population expressed high levels of MHC class II ( 90% ) and CD86 ( 50% ), and 66% of the cells was positive for CD11c, when examined by flow cytometric analysis.
Plasmid DNA
An expression plasmid vector, pcDNA -muc, was prepared by cloning the full -length MUC1 cDNA ( 3.4 kbp ) obtained by digestion with HindIII and BamHI of pHbAPr-1 -muc1, kindly provided by Surinder K Batra ( Duke University Medical Center ), into pcDNA3.1 ( Invitrogen, Carlsbad, CA ). To study the expression of antigen proteins at the vaccination site, pcDNA -GFP -muc was prepared by cloning a PCR product containing an initiation codon followed by two MUC1 tandem repeats into the N -terminus of the green fluorescent protein ( GFP ) coding region of pcDNA3.1 /CT-GFP -TOPO (Invitrogen ).
Transfection of MUC1 cDNA into tumor cell lines
EL4 cells were transfected with pcDNA -muc, pcDNALacZ ( Invitrogen ), or pcDNA3.1 control vector using polycationic reagent ( Qiagen, Santa Clarita, CA ) according to the manufacturer's instructions. Forty -eight hours after transfection, cells were cultured in the conditioned medium supplemented with 800 g /mL G418 ( Gibco BRL ) for 14 days. G418 -resistant cells were harvested and MUC1 -expressing clones, designated EL4 -muc, were obtained by a limiting dilution method.
Vaccination
Female C57BL /6 mice received injection of 100 g of plasmid DNA vaccine dissolved in 50 L of PBS into the hind -leg quadriceps muscle. Three weeks after vaccination, the mice were boosted with the same protocol. In the
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6 ) resuspended in 50 L of PBS were injected simultaneously at the vaccination site.
Enzyme -linked immunosorbent assay ( ELISA )
Mice were vaccinated with 100 g of plasmid DNA twice at an interval of 3 weeks. Seven days after the last immunization, the mice were bled and serum antibody was tested. First, a 96 -well ELISA plate ( Nalgen Nunc International, Roskilde, Denmark ) was coated with 100 L/well of 2 g /mL MUC1 peptides, and 100 L of serially diluted sera ( 1:100 to 1:6400, diluted with PBS ) was distributed to each well of a ELISA plate. The plate was incubated overnight at 48C. After washes with PBS, the plate was incubated with HRP -conjugated anti -mouse IgG or control IgG (ICN Pharmaceutical ) diluted at 1 /1000 for 60 minutes at 378C. After three times of washing with PBS, color was developed by incubation with the substrate solution made of 50 L of 0.05 M o -phenylenediamine and H 2 O 2 . The reaction was stopped by addition of 50 L of 4 N HCl, and the absorbance at 492 nm was measured by microplate reader.
Tumor challenge experiment
For tumor prevention, mice were vaccinated with 100 g of plasmid DNA (in 50 L of PBS ) into the hind -leg quadriceps muscle twice at an interval of 3 weeks. Fourteen days after the last vaccination, the immunized mice were inoculated subcutaneously (s.c. ) in the right flank with either 2Â10 5 EL4 parental cells, EL4 -LacZ, or EL4 -muc cells. The size of the inoculated tumor was monitored twice a week. For tumor regression testing, nontreated mice were inoculated with 1.5Â10 5 EL4 parental cells or MUC1 DNA -or LacZ DNA -transduced cells. Seventy -two hours later, the mice were then injected with 100 g of plasmid DNA with or without activated DCs, intramuscularly, at the same region. The vaccination was repeated every other week. The size of the tumor was monitored twice a week, and the tumor volume was calculated with the following formula: lengthÂwidth 2 /2.
Statistical analysis
Reactivity of mouse sera to antigens in ELISA and the size of the inoculated tumor in a tumor challenge test were compared by Student's t test. Kaplan -Meier curves were generated for time to survival of the mice. Curves for two groups were compared with the log -rank test for equality of survivor functions. P value of less than .05 was considered to be statistically significant.
Results
Induction of antigen -specific antibodies in immunized mice
The reactivity of sera from MUC1 DNA -vaccinated mice ( n= 10 ) to MUC1 peptides was significantly stronger than that of sera from LacZ DNA -vaccinated mice (n = 10) and from normal C57BL /6 mice ( n= 5 ) (MUC1 DNAvaccinated mice versus LacZ DNA -vaccinated mice: P= .001 at 1 /100 dilution and P=.010 at 1/ 400 dilution) ( Fig 1) . All of the 10 mice vaccinated with MUC1 DNA produced anti -MUC1 antibodies (IgM +IgG ); an OD at 1 / 100 dilution under 0.454 (2Â mean in normal mice ) was determined as the normal range. Using antibody to mouse IgG as the secondary antibody in the ELISA determined that both IgM and IgG were responsible for the observed reactivity to MUC1 in 5 of 10 mice possessing anti -MUC1 antibodies (data not shown).
Induction of antigen -specific cellular immunity in vaccinated mice C57BL / 6 mice were vaccinated with MUC1 or LacZ DNA with or without DCs twice at an interval of 3 weeks. Fourteen days after the last immunization, spleen cells obtained from these mice were co -cultured with EL4, EL4 -muc cells, or syngeneic spleen cells pulsed with 10 M Pan-IA peptides for 96 hours. All of the mice vaccinated with MUC1 DNA showed specific responses to MUC1 DNA -transduced EL4 cells, whereas control DNA -vaccinated mice did not respond to parental EL4 or EL4 -muc cells (Fig 2 ) .
Suppression of tumor growth in vivo by vaccination with MUC1 DNA When 2Â10 5 parental EL4 or EL4 -muc cells were inoculated into the mice that had been immunized with MUC1 DNA ( pcDNA -muc ) or pcDNA -LacZ, the size of the tumors was monitored twice a week. All of the mice vaccinated with MUC1 DNA suppressed EL4 -muc tumor growth and completely rejected it ( Fig 3) . In contrast, EL4 -muc cells formed tumors and grew in mice that had been vaccinated with unrelated DNA vaccines, pcDNA -LacZ. EL4 -LacZ cells grew in all the mice vaccinated with MUC1 DNA. These Figure 1 Humoral immunity specific for MUC1 elicited by vaccination with MUC1 DNA in mice. The antibody activity of sera from DNAvaccinated mice ( n = 10 ) and normal mice ( n = 5 ) to MUC1 peptides was examined by ELISA. As a positive control, serially diluted SM3 antibody ( 1.0 -0.015 g / mL ) was used. The same experiments were performed four times. This shows their representative results. *P < .001.
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Tumor suppression by vaccination with DNA and DC K Kontani et al data suggest that prophylactic vaccination with MUC1 DNA can elicit MUC1 -specific immunity, which is sufficient to prevent tumor growth of EL4 -muc cells. To establish a mouse model more applicable to immunotherapy, mice were first inoculated s.c. with tumor cells and then vaccinated with MUC1 DNA after confirmation of tumor establishment. When 1.5Â10 5 EL4 cells or EL4 -muc cells were s.c. inoculated, tumors with 5 -7 mm in diameter were detected at 10-14 days after inoculation. When mice were treated with DNA vaccine at the time of detection of tumors, all mice died within the following 2 weeks ( data not shown). We speculate that the tumor-inoculated mice were cachexic and had weakened general immunity in the 1 -2 weeks after immunization, and they were unable to mount an immune response to suppress tumor growth by the immunization. In order to activate tumor-specific immunity while their general immunity was not weakened, mice were immunized 3 -7 days after the tumor challenge and boosted with the same protocol at intervals of 2 weeks. Contrary to our expectations, tumor growth of MUC1 -transduced cancer cells was not suppressed by this protocol ( Fig 4 ) , the tumor size in LacZ DNAvaccinated mice versus MUC1 DNA -vaccinated mice: P= .8296 on day 21 and P=.9342 on day 28 ). Antitumor immunity elicited by this vaccine protocol was insufficient to suppress tumor growth in mice. To enhance anti -MUC1 immunity, mice received combination of MUC1 DNA and nonprimed, syngeneic DCs at the vaccination site. In these mice, tumor growth was significantly suppressed. Compared (Fig 4 ) , difference was apparent. Survival of these mice was significantly prolonged compared with the mice vaccinated with MUC1 DNA alone or control DNA with or without DCs (P=.0039: MUC1 DNA + DC versus MUC1 DNA; P=.001: MUC1 DNA +DC versus LacZ DNA ) (Fig 5) .
Kinetics of inoculated DCs at the vaccination site
Three days after vaccination with pcDNA -GFP -muc with or without DC inoculation, the muscle tissues at the vaccination site and regional lymph nodes were resected and examined with a fluorescence microscope. In mice that received both DNA vaccine and DCs, many cells expressing GFP were found in the stroma of the resected muscle tissues and in the lymph nodes (Fig 6A and B ) . In mice vaccinated with DNA without DCs, very few cells infiltrated into the stroma of the muscles, and only a few cells expressing GFP were observed in the muscles and lymph nodes ( Fig 6C and  D ) . To identify the GFP -expressing cells, muscle tissues from mice that received DNA vaccine and DCs were examined for MHC class II and CD86 expression by immunofluorescent staining. Many cells with irregular shapes and heterogeneous sizes showed high levels of MHC class II ( Fig 6E ) and CD86 expression (data not shown ), indicating that the dominant population of the cells expressing GFP may be DCs. When muscle tissues from mice that received MUC1 DNA vaccine and DCs were stained with an anti -MUC1 core monoclonal antibody, DF3, many cells in the stroma were positive for MUC1 ( Fig 6F) . In mice vaccinated with MUC1 DNA without DC Figure 6 DCs inoculated at the vaccination site expressed DNA -encoding antigens. Seventy -two hours after vaccination with 100 g of pcDNA -GFP -muc or pcDNA -muc with or without DC inoculation, the muscles at the vaccination site and the paraaortic lymph nodes were resected from the mice. The samples were frozen, sliced, fixed, and then observed under a fluorescence microscope. For immunofluorescent or immunohistochemical staining, sections were incubated with primary antibodies, washed in PBS, and incubated with FITC -or HRP -conjugated secondary antibodies. A: Muscles from mice vaccinated with pcDNA -GFP -muc and DCs; ( B ) lymph nodes from mice vaccinated with pcDNA -GFP -muc and DCs; ( C ) muscles from mice vaccinated with pcDNA -GFP -muc without DCs; ( D ) lymph nodes from mice vaccinated with pcDNA -GFP -muc without DCs; ( E ) muscles from mice vaccinated with pcDNA -muc and DCs that had been stained with anti -MHC class II antibody; ( F ) muscles from mice vaccinated with pcDNA -muc and DCs that had been stained with anti -MUC1 core monoclonal antibody, DF3; ( G ) muscles from mice vaccinated with pcDNA -muc1 without DCs that had been stained with DF3; ( H ) muscles from mice vaccinated with pcDNA -LacZ and DCs that had been stained with DF3.
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Enhancement of tumor suppression via CD4 + T -cell activation by combination of MUC1 DNA and DCs
To assess the effects of the combination, humoral and cellular immune responses to MUC1 antigens in the immunized mice were examined. The antibody activity to MUC1 antigens in sera from mice vaccinated with MUC1 DNA and DCs was not significantly different from that of MUC1 DNA -vaccinated mice (Fig 1) . In a proliferation assay, spleen cells from mice vaccinated with MUC1 DNA and DCs exhibited the enhanced responses to MUC1 antigens: 4 -to 5 -fold in proliferation compared to those from mice vaccinated with MUC1 DNA alone (Fig 7A ) . Populations of the spleen cells responsible for the antigenspecific cell response were suggested to be CD4 + T cells ( Fig 7A and B ) .
Discussion
DNA vaccines have been reported to be beneficial for maintaining high levels of tumor antigen expressions at the vaccination site and for eliciting strong antitumor immunity in hosts. 11 -13 Therefore, DNA vaccines are expected to be useful in immunotherapy for cancer. In experimental mouse models, tumor growth has been successfully suppressed by vaccination with DNA -encoding tumor antigens when tumor cells were challenged in previously vaccinated mice. 14 -17 To establish a mouse model more applicable to clinical anti-cancer immunotherapy, effective DNA vaccines in tumor-bearing mice are needed. However, there have been no reports on eradication of established tumors in mice by DNA vaccination without the use of additional manipulations to modulate the immunogenicity or expression of target antigens. 16, 18, 26 In this study, human MUC1 mucin, which is highly expressed on various cancer cells, i.e., breast, pancreatic, lung, and colon carcinoma cells, was targeted as a tumor antigen. 19 -22,27 Its antigenic epitopes, which are located within the tandem repeat domain on the core protein, have been reported to be recognized by CTLs in an MHCunrestricted, as well as an MHC -restricted, manner. 24,28 -31 It has also been reported that CTLs which recognize MUC1 can be induced in mice whose MHC haplotypes were H-2 b,d,k . 23 For these reasons, MUC1 is thought to be useful in targeting as a tumor antigen in an experimental mouse model for clinical immunotherapy. Vaccination with MUC1 DNA into C57BL/6 mice (H-2 b ) induced both humoral and cellular immunity specific for MUC1 ( Figs 1 and 2) . The induced anti -MUC1 immunity was sufficiently strong to prevent tumor growth, but not strong to suppress established tumor growth. To enhance the antitumor immunity by MUC1 DNA vaccination, syngeneic DCs were inoculated simultaneously at the vaccination site, namely at quadriceps muscle, because activated DCs distributed at the vaccination site have been reported to be responsible for priming antigen -specific T lymphocytes. 32 Simultaneous DC inoculation is expected to increase the number of APCs capable The same experiments were performed four times. This shows their representative results. **P < .01, *P < .05, n.s.: Not significant.
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In this paper, as a result, tumor growth was significantly suppressed by the therapy with a combination of MUC1 DNA vaccine and DCs in the MUC1 + tumor-bearing mice, accompanying prolonged survival (Fig 4) . In these mice, many DCs expressing high levels of MUC1 were found at the vaccination site and in regional lymph nodes by immunohistochemical study ( Fig 6A, B and E ) . It is important to note that these CD86 + and MHC class II + cells were homogeneously and diffusely distributed at the vaccinated site. These findings suggest that many of the inoculated DCs were able to process MUC1 antigen at the vaccination site. Considerable number of DCs pulsed with MUC1 antigen settled at the vaccination site, whereas some of the DCs migrated into regional lymph nodes, both DCs presenting MUC1 molecule to T lymphocytes. In Figure 7A , spleen cells from mice receiving both MUC1 DNA and DCs were found to respond intensively to EL4 -muc cells, when 3 H thymidine uptake was measured. Spleen cells (presumably CD4 + cell ) pulsed with Pan -IA peptides demonstrated proliferation in the similar extent. Furthermore, the T-cell response to MUC1 antigens was markedly inhibited by anti -CD4 antibody (Fig 7B ) . These findings suggest that combination of MUC1 DNA and DCs could augment the helper function of CD4 + T lymphocytes, resulting in the enhanced cytotoxic activity against MUC1. Recently, it has been reported that DCs, as APCs, play central roles in activation of CTLs. Autologous DCs pulsed with tumor antigens or DNA -encoding tumor antigen resulted in successful suppression of tumor growth. 33 -36 These findings indicate that DCs loaded with abundant tumor antigens have the ability to induce strong antitumor immunity in vivo. However, in vitro preparation of DNA -transduced DCs, which involves separation of DCs from peripheral blood of cancer patients, transfection of DNA into the DCs, and then selection and propagation of the transduced DCs, is cumbersome, expensive, and needs a long time. This new DNA vaccination protocol combining DNA vaccine and naive DCs could overcome these difficulties, contributing greatly to the induction of strong antitumor immunity capable of suppressing tumor growth.
